Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Anyone who needs insulin to treat diabetes knows that the cost of the drug has skyrocketed in the last few years. The reason for the sharp ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Eli Lilly and ... using basal insulin for the first time (insulin naïve) and in those who have switched from daily basal insulin injections, respectively. In these long-term treat-to-target ...

"I thought: No insulin? Death is imminent," Wright said. Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi ... diabetes need short-acting insulin.

"I thought: No insulin? Death is imminent," Wright said. Three drug companies dominate the U.S. insulin market: Novo Nordisk, ...

Some diabetes patients this year have had trouble finding their preferred insulin ... to short-acting insulin. Which insulin brands are in shortage and why? Earlier this year, Eli Lilly reported ...

While Mounjaro and Zepbound are Eli Lilly and Company's leading growth plays, there are others that are contributing to the upside. One example of this is Humalog, which is a fast-acting insulin ...

High-flying aircraft experience turbulence from time to time. It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on ...

Here's why Eli Lilly is a no-brainer stock to buy on ... with sales rising 18% to nearly $880 million. Even Lilly's insulin product Humalog, which was first approved by the U.S. Food and Drug ...